Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. / Mohammad, H.; Madsen, K.; Graumann, O.; Loya, A. C.; Jensen, N.; Dahlrot, R. H.
I: Urology Case Reports, Bind 40, 101880, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
AU - Mohammad, H.
AU - Madsen, K.
AU - Graumann, O.
AU - Loya, A. C.
AU - Jensen, N.
AU - Dahlrot, R. H.
PY - 2022
Y1 - 2022
N2 - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.
AB - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.
KW - Metanephric adenoma
KW - Tyrosine kinase inhibitor
KW - Oncology
KW - Renal tumour
KW - ADENOMA
U2 - 10.1016/j.eucr.2021.101880
DO - 10.1016/j.eucr.2021.101880
M3 - Journal article
C2 - 34692420
VL - 40
JO - Urology Case Reports
JF - Urology Case Reports
SN - 2214-4420
M1 - 101880
ER -
ID: 290109540